US2021059931A1PendingUtilityA1

Method and composition for treating ocular hypertension and glaucoma

60
Assignee: SANTEN PHARMACEUTICAL CO LTDPriority: May 30, 2008Filed: Nov 11, 2020Published: Mar 4, 2021
Est. expiryMay 30, 2028(~1.8 yrs left)· nominal 20-yr term from priority
Inventors:Timo ReunamakiPertti PellinenOlli OksalaKari Lehmussaari
A61P 27/06A61K 47/10A61K 47/26A61K 31/5575A61K 9/0048A61P 27/02A61K 47/183A61K 2800/80A61K 47/02Y02A50/30A61P 43/00A61K 9/08A61P 9/12
60
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to an ophthalmic aqueous composition containing PGF2α analogues for treating ocular hypertension and glaucoma, to a method for treating ocular hypertension and glaucoma by administering said composition to a subject in need of such treatment, and to a method for increasing aqueous solubility and stability of PGF2α analogues in an aqueous composition.

Claims

exact text as granted — not AI-modified
1 . A method for treating ocular hypertension and glaucoma to a subject in need thereof, by administrating an ophthalmic aqueous solution comprising 0.0015% w/v tafluprost as an active ingredient, 0.075% w/v polysorbate 80 and 0.05% w/v disodium edetate, wherein the ophthalmic aqueous solution is stable and bioavailable at room temperature without benzalkonium chloride. 
     
     
         2 . A method for treating ocular hypertension and glaucoma to a subject in need thereof according to  claim 1 , wherein the ophthalmic aqueous solution is stable and bioavailable at least for 4 weeks at room temperature. 
     
     
         3 . A method for treating ocular hypertension and glaucoma to a subject in need thereof according to  claim 1 , wherein the ophthalmic aqueous solution is stable and bioavailable at least for 12 months at room temperature. 
     
     
         4 . A method for treating ocular hypertension and glaucoma to a subject in need thereof according to  claim 1 , wherein the ophthalmic aqueous solution is stable and bioavailable at least for 4 weeks at 5° C. 
     
     
         5 . A method for treating ocular hypertension and glaucoma to a subject in need thereof according to  claim 1 , wherein the ophthalmic aqueous solution is stable and bioavailable at least for 30 months at 5° C. 
     
     
         6 . A method for treating ocular hypertension and glaucoma to a subject in need thereof according to  claim 1 , wherein the ophthalmic aqueous solution is packaged in a container made of a low density polyethylene. 
     
     
         7 . A method for treating ocular hypertension and glaucoma to a subject in need thereof according to  claim 1 , wherein the ophthalmic aqueous solution is packaged in a single dose or unit dose container.

Join the waitlist — get patent alerts

Track US2021059931A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.